• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>The journal of clinical psychiatry >Rapid resolution of obsessions after an infusion of intravenous ketamine in a patient with treatment-resistant obsessive-compulsive disorder.
【24h】

Rapid resolution of obsessions after an infusion of intravenous ketamine in a patient with treatment-resistant obsessive-compulsive disorder.

机译：对患有难治性强迫症的患者进行静脉氯胺酮输注后，可以快速解决困扰。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Obsessive-compulsive disorder (OCD) is a leading cause of illness-related disability.1 Identifying more effective treatments with faster onset of action would be a major advance. Medications thought to modulate the glutamate system are promising new agents; for example, open trials of riluzole, memantine, and minocycline as augmentation to serotonin reuptake inhibitors (SRIs) suggest that up to half of OCD patients may experience reductions in symptoms.2"7 We chose to test intravenous keta-mine (a noncompetitive N-methyl-D-aspartate [NMDA] receptor antagonist) in an OCD patient for 3 reasons: (1) it is known to modulate the glutamate system, having some mechanistic similarity to memantine8; (2) mice with a genetic deletion in a postsynaptic scaffolding protein (SAPAP3) have OCD-like compulsive behavior thought to be caused by increased NMDA activity, and ketamine decreases NMDA activity; and (3) ketamine has been safely used in patients with depression and can relieve depressive symptoms in hours.
机译：强迫症（OCD）是与疾病相关的残疾的主要原因。1识别出起效更快，更有效的治疗方法将是一大进步。被认为可以调节谷氨酸系统的药物是有前途的新药。例如，对利鲁唑，美金刚和米诺环素增强5-羟色胺再摄取抑制剂（SRI）的开放试验表明，多达一半的强迫症患者可能会出现症状减轻。2“ 7我们选择测试静脉内的Keta-mine（非竞争性-甲基-D-天冬氨酸[NMDA]受体拮抗剂在OCD患者中的原因有3个：（1）已知其调节谷氨酸系统，与美金刚有一定的机械相似性;（2）突触后基因缺失的小鼠脚手架蛋白（SAPAP3）具有强迫性行为，被认为是由NMDA活性增加引起的，氯胺酮会降低NMDA活性;（3）氯胺酮已被安全地用于抑郁症患者，可在数小时内缓解抑郁症状。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号